Here is the updated Q&A for Sep 2024. This represents about 10 hours of work, summarizing and structuring information for Opthea GPT. I have done my best to ensure the information is correct. Let me know if there is anything incorrect or requiring update.

Opthea Q&A

Company Overview and Leadership

Q A1: Where is Opthea Limited headquartered, and when was it started?

A: Opthea Limited is headquartered in Melbourne, Australia, with a presence in Princeton, New Jersey, USA. The company was founded in 1984 as Circadian Technologies Limited and rebranded as Opthea Limited in 2015.
.

Q A2: What was Circadian Technologies focused on before 2015?

A: Circadian Technologies focused on biotechnology and life sciences, particularly cancer and angiogenesis research. The company developed therapies targeting vascular endothelial growth factors (VEGF) for cancer treatment, laying the foundation for Opthea’s focus on retinal diseases.
.

Q A3: What is the role of Opthea's Medical Advisory Board, and who are its members?

A: Opthea’s Medical Advisory Board (MAB) consists of 10 renowned retina experts, chaired by Dr. Arshad M. Khanani (USA). Members include:
.

• Dr. Arshad M. Khanani (USA) - Chair
  • Education: MD from Aga Khan University Medical College; MA in molecular biology.
  • Current Role: Managing Partner at Sierra Eye Associates, and Clinical Associate Professor at the University of Nevada, Reno.
  • Expertise: Renowned retina specialist with a focus on clinical trials and innovative therapies for retinal diseases.
• Dr. David S. Boyer (USA)
  • Education: MD from Chicago Medical School; ophthalmology residency at the University of Southern California.
  • Current Role: Senior Partner at Retina-Vitreous Associates Medical Group, Los Angeles.
  • Expertise: Extensive experience in clinical research for retinal diseases, particularly in macular degeneration.
• Prof. Andrew Chang (Australia)
  • Education: MBBS (Hons) and PhD from the University of Sydney.
  • Current Role: Vitreoretinal surgeon and ophthalmologist at Sydney Retina Clinic and Sydney Eye Hospital.
  • Expertise: Focuses on retinal surgery and the treatment of diabetic retinopathy and macular degeneration.
• Prof. Frank G. Holz (Germany)
  • Education: MD from the University of Heidelberg; Fellow of the European Board of Ophthalmology.
  • Current Role: Professor and Chairman of Ophthalmology at the University of Bonn.
  • Expertise: Specializes in age-related macular degeneration (AMD) and retinal imaging techniques.
• Prof. Anat Loewenstein (Israel)
  • Education: MD and MHA from the Tel Aviv University; residency in ophthalmology at Tel Aviv Medical Center.
  • Current Role: Director of the Department of Ophthalmology at Tel Aviv Medical Center, and Vice Dean at Tel Aviv University.
  • Expertise: Leading expert in retinal disease, focusing on AMD and diabetic retinopathy.
• Dr. Dante Pieramici (USA)
  • Education: MD from Johns Hopkins University School of Medicine.
  • Current Role: Managing Partner and Medical Director of Clinical Research at California Retina Consultants.
  • Expertise: Specialist in vitreoretinal surgery and clinical trials for AMD and diabetic retinopathy.
• Dr. Carl Regillo (USA)
  • Education: MD from Harvard Medical School; residency in ophthalmology at Wills Eye Hospital.
  • Current Role: Director of the Retina Service at Wills Eye Hospital and Professor at Thomas Jefferson University.
  • Expertise: Known for his work in clinical research and surgical treatment of retinal disorders.
• Dr. Patricio G. Schlottmann (Argentina)
  • Education: MD from the University of Buenos Aires; specialized training in retina and vitreous surgery.
  • Current Role: Ophthalmology Director at the Charles Research Center of Ophthalmology in Buenos Aires.
  • Expertise: Focuses on retinal diseases, particularly in developing and implementing new surgical techniques.
• Prof. Tien Y. Wong (China)
  • Education: MD from the National University of Singapore; PhD from Johns Hopkins University.
  • Current Role: Chair Professor and Founding Head of Tsinghua Medicine at Tsinghua University, Beijing.
  • Expertise: World-renowned researcher in diabetic retinopathy and cardiovascular disease epidemiology.
• Prof. Eric Souied (France)
  • Education: MD and PhD from the University of Paris-Est Creteil.
  • Current Role: Head of the Ophthalmology Department at Intercommunal Hospital of Créteil.
  • Expertise: Specializes in AMD and genetic predispositions to retinal diseases, with extensive research in this field.

.

Q A4: Who was the CEO of Opthea before Dr. Frederic Guerard?

A: Before Dr. Frederic Guerard, Megan Baldwin, PhD, served as the CEO of Opthea Limited from 2015 until August 2022. She transitioned to the role of Chief Scientific Officer (CSO) when Dr. Guerard took over.

.

Q A5: Who are the key C-suite executives and medical officers at Opthea, and when did they join?

A: Key executives include:

• Dr. Frederic Guerard, PharmD (Chief Executive Officer): Joined as CEO on August 1, 2022.
• Megan Baldwin, PhD (Founder and Chief Scientific Officer): Originally served as CEO from 2015 and transitioned to CSO in August 2022.
• David Muller (Chief Financial Officer): Joined as CFO in February 2023.
• Dr. Arshad M. Khanani, MD, MA, FASRS (Chief Medical Advisor): Appointed as Chief Medical Advisor in July 2023.